These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36052082)

  • 1. The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report.
    Gao Z; Xu Y; Zu J; Wang X; Sun C; Qiu S; Guo Y; Ma K
    Front Immunol; 2022; 13():946829. PubMed ID: 36052082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report.
    Xu Y; Cai Y; Zu J; Wang X; Wang Y; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Immunotherapy; 2020 Feb; 12(3):175-181. PubMed ID: 32064977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
    Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
    Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.
    Yun SJ; Oh IJ; Park CK; Kim YC; Kim HB; Kim HK; Hong AR; Kim IY; Ahn SJ; Na KJ; Choi YD
    Transl Lung Cancer Res; 2020 Aug; 9(4):1585-1590. PubMed ID: 32953529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
    Rivera N; Boada A; Bielsa MI; Fernández-Figueras MT; Carcereny E; Moran MT; Ferrándiz C
    JAMA Dermatol; 2017 Nov; 153(11):1162-1165. PubMed ID: 28700789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L
    JAMA Oncol; 2019 Jul; 5(7):1043-1047. PubMed ID: 31021392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
    Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 9. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
    Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
    Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.
    Birnbaum MR; Ma MW; Casey MA; Amin BD; Jacobson M; Cheng H; McLellan BN
    J Drugs Dermatol; 2017 Oct; 16(10):1047-1049. PubMed ID: 29036261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy may exacerbated anti-programmed cell death 1 treatment induced vitiligo: A case report.
    Chen C; Chang Q; Wang B; Wang Y; Zhang Z; Wang X
    Skin Health Dis; 2024 Feb; 4(1):e287. PubMed ID: 38312255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
    Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
    J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
    Domblides M; Geier M; Decroisette C; Descourt R
    Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.
    Hasan Ali O; Bomze D; Ring SS; Berner F; Fässler M; Diem S; Abdou MT; Hammers C; Emtenani S; Braun A; Cozzio A; Mani B; Jochum W; Schmidt E; Zillikens D; Sadik CD; Flatz L
    J Am Acad Dermatol; 2020 Apr; 82(4):854-861. PubMed ID: 31449902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.